Abstracts tagged "Cryoglobulinemia"

Abstract Number: 1104 • ACR Convergence 2024
Long-term Follow-up of Patients with Positive Cryofibrinogen Test During the COVID-19 Era
Carmen Lasa Teja¹, Amparo Sánchez-López², María Enriqueta Peiró³, Mónica Renuncio-García⁴, Adrián Martín-Gutiérrez⁵, Carmen Secada Gómez⁶, Juan Irure-Ventura⁷, Marcos Lopez-Hoyos⁸ and Ricardo Blanco-Alonso⁹, ¹Hospital Universitario Marqués de Valdecilla, Riotuerto, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Immunology, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ⁶Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁷Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Cantabria, Spain, ⁸Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Spain, ⁹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: There have been increasing reports of cutaneous manifestations during COVID‐19 pandemic. An increase in awareness by physicians made them to increase the number of…
Abstract Number: 2514 • ACR Convergence 2024
The Pattern of Renal Involvement in Relapsing Cryoglobulinemic Vasculitis After Successful Sustained Viral Response by Direct-Acting Antiviral Treatments
Mohamed Tharwat Hegazy¹, Ahmed Fayed¹ and Gaafar Ragab², ¹Faculty of Medicine, Cairo University, Cairo, Egypt, ²Cairo University, Egypt, Cairo, Egypt
Background/Purpose: Interferon-free Direct Acting Antiviral (DAA) treatments proved to be effective for the treatment of HCV-induced Cryoglobulinemic Vasculitis (HCV-Cryovas). Some reports showed relapses of HCV-Cryovas…
Abstract Number: 0205 • ACR Convergence 2023
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy
Jamie Chieh Lo¹, Ying-Nan Tsai², Cheng-Hao Tseng³, Yao-Chun Hsu⁴ and Song-Chou Hsieh⁵, ¹School of Medicine, I-Shou University, Kaohsiung, Taiwan, ²Department of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ³Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ⁴I-Shou University School of Medicine, E-Da Hospital Center of Liver Diseases, Kaohsiung, Taiwan, ⁵National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Chronic hepatitis C virus (HCV) infection is associated with autoimmune extrahepatic manifestations including increased production of autoantibodies such as rheumatoid factor (RF). Prior to…
Abstract Number: 1281 • ACR Convergence 2022
Less Than Half of Cryoglobulin Tests Ordered at a Tertiary Hospital Network Are Successfully Completed: An Opportunity for Improvement
Joo Young (Esther) Lee¹, Alexis Baass², Sasha Bernatsky³, Evelyne Vinet² and Arielle Mendel², ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Cryoglobulin detection is essential for the diagnosis of cryoglobulinemic vasculitis, a condition leading to high healthcare use, organ damage, and even death. Successful cryoglobulin…
Abstract Number: 1688 • 2019 ACR/ARP Annual Meeting
Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial
Benjamin Terrier¹, Jonathan London ², Fabrice Bonnet ³, Diane Cerutti ⁴, Nathalie Costedoat-Chalumeau ⁵, Elisabeth Diot ⁶, Yasmina Ferfar ⁷, Aurélie Hummel ⁸, Gilles Kaplanski ⁹, Isabelle Marie ¹⁰, Thomas Quémeneur ¹¹, Patricia Rullier ¹², Patricia Senet ¹³, Noémie Le Gouellec ¹⁴, Julie Lejeune ⁷, David Saadoun ¹⁵ and Patrice Cacoub ¹⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ²Croix Saint-Simon Hospital, Paris, France, ³CHU, Bordeaux, France, ⁴CH, Toulon, France, ⁵Cochin University Hospital, Paris, France, ⁶APHP, Tours, France, ⁷Pitié-Salpétrière Hospital, Paris, France, ⁸APHP, Paris, France, ⁹CHU, Marseille, France, ¹⁰CHU, Rouen, France, ¹¹CH Valenciennes, Valenciennes, France, ¹²CHU, Montpellier, France, ¹³Tenon Hospital, Paris, France, ¹⁴CH, Valenciennes, France, ¹⁵AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France
Background/Purpose: A previous retrospective study suggested superiority of glucocorticoids (GCs) plus rituximab (RTX) compared to GCs alone to induce complete clinical response in non-infectious cryoglobulinemia…
Abstract Number: 1722 • 2019 ACR/ARP Annual Meeting
Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy
Peter Gorevic¹, Frank Eng ², Andrea Branch ³, Ahmed Elshamy ⁴, Erin Doyle ² and Thomas Schiano ², ¹Mount Sinai Hospital, New York, ²Mount Sinai Medical Center, New York, ³Mount Sinai Medical School, New York, ⁴California Northstate University, Sacramento
Background/Purpose: BACKGROUND. Mixed Cryoglobulins (MCs) are cold precipitable Rheumatoid Factors (RFs) that provide a biomarker for immune complex formation, particularly associated with chronic Hepatitis C…
Abstract Number: 1723 • 2019 ACR/ARP Annual Meeting
Mixed Cryoglobulinaemia Since the Advent of New Direct-acting Antivirals for Hepatitis C Infection: Clinical Characteristics, Etiologies and Biological Features in 679 Patients
Gonçalo Boleto¹, Pascale Ghillani-Dalbin ², Lucile Musset ², Patrice Cacoub ¹ and David Saadoun ¹, ¹AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ²Department of Immunology, UF d’Immunochimie et d’autoimmunité, APHP, Groupe Hospitalier Pitié-Salpétrière, Paris, France, Paris, France
Background/Purpose: Previously chronic hepatitis C virus (HCV) infection was accountable for 80-90% of cases of mixed cryoglobulinemia (MC). The advent of direct-acting antivirals (DAA) has…
Abstract Number: 829 • 2018 ACR/ARHP Annual Meeting
DNA Damage and Repair in Patients with Cryoglobulinemic Vasculitis Treated with Direct Anti-HCV Drugs
Mohamed Tharwat Hegazy¹, Walaa Allam², Mohamed A Hussein¹, Naguib Zoheir³, Luca Quartuccio⁴, Patrice Cacoub⁵, Wahid Doss⁶, Mona I. Ellawindi⁷, Mary Fawzy¹, Loïc Guillevin⁸, Ahmed El Ray⁹, Maissa El Said El Raziky^10,11, Magdy El Serafy⁶, Sherif El Khamisy^2,12 and Gaafar Ragab¹, ¹Internal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ²Center for Genomics, Zewail City of Science and Technology, Giza, Egypt, Giza, Egypt, ³Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁴Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ⁵Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, ⁶Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁷Community Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁸Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁹Theodor Bilharz Research Institute, Cairo, Egypt, Cairo, Egypt, ¹⁰Fatimid Cairo hospital, Cairo, Egypt, Cairo, Egypt, ¹¹Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, cairo, Egypt, ¹²Krebs Institute, University of Sheffield, Sheffield, S10 2TN, UK, Sheffield, United Kingdom
DNA Damage and Repair in Patients with Cryoglobulinemic Vasculitis Treated with Direct Anti-HCV Drugs Background/Purpose: Direct Acting Antiviral (DAA) agents were shown to be effective…
Abstract Number: 17L • 2016 ACR/ARHP Annual Meeting
Sofosbuvir Plus Daclatasvir for Hepatitis C Virus Associated Cryoglobulinemia Vasculitis
David Saadoun¹, yasmina ferfar¹, AS Bouyer², laurent alric³, christophe hezode⁴, SN Si Ahmed⁵, L Musset⁶, Luc De Saint Martin Pernot⁷, SN Pol⁸, Dominique Larrey⁹, T Poynard¹⁰ and Patrice Cacoub², ¹Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ²Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, paris, France, ³Department of Internal Medicine-Digestive, Centre hospitalier universitaire Purpan, UMR 152 Toulouse 3 University, Toulouse, toulouse, France, ⁴Department of Hepatology, APHP, Hôpital Henri Mondor, Créteil, creteil, France, ⁵Department of Hepatology, Hôpital Orléans, Orléans, Orleans, France, ⁶Department of Immunology, UF d’Immunochimie et d’autoimmunité, APHP, Groupe Hospitalier Pitié-Salpétrière, Paris, France, paris, France, ⁷Department of internal medicine, CHRU Brest, Brest, France, ⁸Department of Hepatology, APHP, Hôpital Cochin, Paris, paris, France, ⁹Department of hepatology, CHRU Montpellier, France, montpellier, France, ¹⁰Department of Hepatology, APHP, Groupe Hospitalier Pitié-Salpétrière, Paris, paris, France

Background/Purpose: Hepatitis C virus (HCV) is the aetiological agent for most cases of cryoglobulinemia vasculitis. Interferon containing regimens are associated with important side effects and…
Abstract Number: 2977 • 2016 ACR/ARHP Annual Meeting
Treatment of Cryoglobulinemic Vasculitis with Sofosbuvir in Four Combination Protocols
Mohamed Tharwat Hegazy¹, Mohamed A Hussein¹, Luca Quartuccio², Mary Fawzy¹, Naguib Zoheir³, Mona I. Ellawindi⁴, Milena Bond², Cesare Mazzaro⁵, Ahmed El Ray⁶, Maissa El Said El Raziky^7,8, Magdy El Serafy⁹, Wahid Doss⁹, Patrice Cacoub¹⁰, Loïc Guillevin¹¹, Salvatore De Vita², Sherif El Khamisy¹² and Gaafar Ragab¹, ¹Internal Medicine, Internal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ²Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, ³Clinical and Chemical Pathology Department, Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁴Community Medicine, Community Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁵Internal Medicine, Pordenone Hospital, Italy, pordenone, Italy, ⁶Theodor Bilharz Research Institute, Cairo, Egypt, Cairo, Egypt, ⁷Fatimid Cairo hospital, Cairo, Egypt, Cairo, Egypt, ⁸Tropical Medicine, Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, cairo, Egypt, ⁹Tropical Medicine, Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁰Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ¹¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ¹²Zewail city of Science and Technology, Egypt, Giza, Egypt
Background/Purpose: Cryoglobulinemic Vasculitis (CV) is a systemic vasculitis affecting small and medium-sized vessels. Following emergence of direct acting antiviral drugs, which paved the way to…
Abstract Number: 628 • 2015 ACR/ARHP Annual Meeting
Poor Prognosis of Patients with Primary Sjögren Syndrome Who Fulfilled at Diagnosis the Classification Criteria for Concomitant Cryoglobulinemic Vasculitis
Soledad Retamozo^1,2, Hoda Gheitasi³, Luca Quartuccio⁴, Belchin Kostov⁵, Laura Corazza⁴, Albert Bové³, Antoni Sisó-Almirall⁵, Myriam Gandía³, Manuel Ramos-Casals¹, Salvatore De Vita⁶ and Pilar Brito-Zerón¹, ¹Department of Autoimmune Diseases, CELLEX-IDIBAPS, Hospital Clínic, Barcelona, Barcelona, Spain, ²Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ³Department of Autoimmune Diseases, IDIBAPS, Hospital Clínic, Barcelona, Spain, ⁴S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ⁵Primary Care Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Primary Care Centre Les Corts, CAPSBE, Barcelona, Spain, ⁶Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy
Background/Purpose: To evaluate the fulfilment of classification criteria for cryoglobulinemic vasculitis (CV) at diagnosis in a large cohort of patients with primary Sjögren syndrome (SS)…
Abstract Number: 3228 • 2015 ACR/ARHP Annual Meeting
Sofosbuvir Plus Ribavirin for Hepatitis C Virus Associated Cryoglobulinemia Vasculitis: Vascuvaldic Study
David Saadoun¹, V Thibault², L Alric³, C Guillaud⁴, H Izzedine², M Costopoulos², L Musset², H Fontaine⁵, C Hezode⁴, S Pol⁵, T Poynard², P Cacoub² and SN SI Ahmed⁶, ¹Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France, ²CHU Pitie Salpetriere, Paris, France, ³CHU Toulouse, Toulouse, France, ⁴CHU H Mondor, Creteil, France, ⁵CHU Cochin, Paris, France, ⁶CH Orleans, Orleans, France
Background/Purpose: Hepatitis C virus (HCV) is the etiologic agent for most cases of cryoglobulinemia vasculitis (Cryovas). Interferon–containing regimens are associated with important side effects and…
Abstract Number: 2855 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Rituximab Retreatment Regimen at Clinical Relapse in Severe Cryoglobulinemic Vasculitis
Luca Quartuccio¹, Francesca Zuliani², Patrizia Scaini³, Marco Lenzi⁴, Antonio Tavoni⁵, Marco Sebastiani⁶, Teresa Urraro⁷, Francesco Saccardo⁸, Costanza Sbreglia⁹, Pietro Pioltelli¹⁰, Paolo Fraticelli¹¹, Davide Filippini¹², Salvatore Scarpato¹³, Oreste Perrella⁹, Armando Gabrielli¹⁴, Dario Roccatello¹⁵, Anna Linda Zignego¹⁶, Clodoveo Ferri¹⁷, Stefano Bombardieri¹⁸, Maurizio Pietrogrande¹⁹, Massimo Galli²⁰, Giuseppe Monti⁸ and Salvatore De Vita¹, ¹Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ²Rheumatology Clinic, University Hospital of Udine, Udine, Italy, ³Nephrology, Spedali Civili di Brescia, Brescia, Italy, ⁴University of Bologna, Bologna, Italy, ⁵Rheumatology Clinic, University of Pisa, Pisa, Italy, ⁶Rheumatology Clinic, University of Modena and Reggio Emilia, Modena, Italy, ⁷Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁸Internal Medicine Unit, Saronno Hospital, Azienda Ospedaliera di Busto Arsizio, Saronno (VA), Italy, ⁹Rheumatology Unit, AO Cotugno, Naples, Italy, ¹⁰Hematology, S.Gerardo Hospital, Monza, Italy, ¹¹Istituto di Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, ¹²Rheumatology Unit, Ospedale Niguarda Ca’ Granda, Milan, Italy, ¹³Rheumatology Unit, M. Scarlato Hospital, Scafati, Salerno, Italy, ¹⁴Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy, ¹⁵CORSO RAFFAELLO 30, UNIVERSITY OF TURIN (ITALY), TURIN, Italy, ¹⁶University of Florence, Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹⁷Internal Med/Rheumatology, Univ Modena Reggio Emilia, Modena, Italy, ¹⁸Rheumatology Unit, University of Pisa, Pisa, Italy, ¹⁹Internal Medicine Unit, Policlinico San Marco, Bergamo, Italy, ²⁰Istituto di Malattie Infettive e Tropicali, Università di Milano c/o Ospedale L. Sacco, Milano, Italy
Background/Purpose: Two independent controlled randomized trials recently reported the efficacy and safety of rituximab (RTX) monotherapy in severe cryoglobulinemic vasculitis (CV) (1, 2), with one…
Abstract Number: 2639 • 2013 ACR/ARHP Annual Meeting
Long-Term Outcome of Monoclonal (type 1) Cryoglobulinemia
Antoine Néel¹, François Perrin¹, Olivier Decaux², Thomas Dejoie³, Maxime Halliez³, Béatrice Mahé⁴, Thierry Lamy⁵, Fadi Fakhouri⁶, Patrick Jego², Christian Agard¹, Cécile Vigneau⁷, Lucienne Guenet⁸, Bernard Grosbois⁹, Philippe Moreau⁴ and Mohamed Hamidou¹, ¹Internal Medicine Department, Nantes University Hospital, Nantes, France, ²Department of Internal Medicine, Rennes University Hospital, Rennes, France, ³Biochemistry Laboratory, Nantes University Hospital, Nantes, France, ⁴Hematology, Nantes University Hospital, Nantes, France, ⁵Hematology, Rennes University Hospital, Rennes, France, ⁶Nephrology, Nantes University Hospital, Nantes, France, ⁷Nephrology, Rennes University Hospital, Rennes, France, ⁸Biochemistry Laboratory, Rennes University Hospital, Rennes, France, ⁹Internal Medicine Department, Rennes University Hospital, Rennes, France
Background/Purpose: To investigate long-term outcome of symptomatic type 1 cryoglobulinemia and its determinants. Methods: Retrospective analysis of a prospective cohort from 2 French university hospitals.…
Abstract Number: 2640 • 2013 ACR/ARHP Annual Meeting
VERY LONG-TERM Effects Of The “4 PLUS2 Infusion PROTOCOL” Of Rituximabalone In Patients With HCV-Associatedmixed Cryoglobulinemia With Diffusemembranoproliferative Glomerulonephritis,Severe Polyneuropathy and Necrotic Ulcersof Skin
Dario Roccatello¹, Savino Sciascia¹, Simone Baldovino² and Daniela Rossi¹, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Centro di Ricerche di Immunologia Clinica ed Immunopatologia e Documentazione su Malattie Rare (CMID), Università di Torino, Torino, Italy
Background/Purpose: Mixed cryoglobulinemia syndrome (MCs) is a systemic vasculitischaracterized by multiple organ involvement due to the vascular deposition ofIgMk/IgG cryoglobulins. B cells expansion usually triggered…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].